Pacific Biosciences Of California Return on Tangible Equity 2010-2024 | PACB
Current and historical return on tangible equity values for Pacific Biosciences Of California (PACB) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Pacific Biosciences Of California Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2024-12-31 | $-0.31B | $-0.20B | 109.15% |
| 2024-09-30 | $-0.39B | $-0.35B | 136.69% |
| 2024-06-30 | $-0.40B | $-0.32B | 166.15% |
| 2024-03-31 | $-0.30B | $-0.26B | 144.70% |
| 2023-12-31 | $-0.31B | $-0.22B | 179.01% |
| 2023-09-30 | $-0.31B | $-0.16B | 170.48% |
| 2023-06-30 | $-0.32B | $-0.18B | 168.56% |
| 2023-03-31 | $-0.32B | $-0.13B | 178.27% |
| 2022-12-31 | $-0.31B | $-0.26B | 185.21% |
| 2022-09-30 | $-0.30B | $-0.19B | 265.48% |
| 2022-06-30 | $-0.20B | $-0.14B | 344.30% |
| 2022-03-31 | $-0.17B | $-0.09B | -435.00% |
| 2021-12-31 | $-0.18B | $-0.03B | -136.62% |
| 2021-09-30 | $-0.04B | $0.02B | -16.14% |
| 2021-06-30 | $-0.08B | $0.26B | -30.71% |
| 2021-03-31 | $-0.06B | $0.28B | -30.03% |
| 2020-12-31 | $0.03B | $0.34B | 20.53% |
| 2020-09-30 | $-0.05B | $0.13B | -64.56% |
| 2020-06-30 | $-0.05B | $0.04B | -98.55% |
| 2020-03-31 | $-0.05B | $0.06B | -87.60% |
| 2019-12-31 | $-0.08B | $0.06B | -121.30% |
| 2019-09-30 | $-0.12B | $0.05B | -136.90% |
| 2019-06-30 | $-0.11B | $0.08B | -106.47% |
| 2019-03-31 | $-0.11B | $0.10B | -102.35% |
| 2018-12-31 | $-0.10B | $0.11B | -94.93% |
| 2018-09-30 | $-0.09B | $0.13B | -91.63% |
| 2018-06-30 | $-0.09B | $0.09B | -96.00% |
| 2018-03-31 | $-0.09B | $0.10B | -91.63% |
| 2017-12-31 | $-0.09B | $0.09B | -100.00% |
| 2017-09-30 | $-0.09B | $0.10B | -98.11% |
| 2017-06-30 | $-0.09B | $0.12B | -93.22% |
| 2017-03-31 | $-0.08B | $0.07B | -86.43% |
| 2016-12-31 | $-0.07B | $0.09B | -76.64% |
| 2016-09-30 | $-0.06B | $0.10B | -59.46% |
| 2016-06-30 | $-0.04B | $0.11B | -46.15% |
| 2016-03-31 | $-0.03B | $0.09B | -50.42% |
| 2015-12-31 | $-0.03B | $0.07B | -65.61% |
| 2015-09-30 | $-0.05B | $0.04B | -115.29% |
| 2015-06-30 | $-0.06B | $0.03B | -131.87% |
| 2015-03-31 | $-0.07B | $0.04B | -129.47% |
| 2014-12-31 | $-0.07B | $0.06B | -108.64% |
| 2014-09-30 | $-0.06B | $0.05B | -99.61% |
| 2014-06-30 | $-0.08B | $0.06B | -104.17% |
| 2014-03-31 | $-0.08B | $0.08B | -92.40% |
| 2013-12-31 | $-0.08B | $0.07B | -86.67% |
| 2013-09-30 | $-0.08B | $0.08B | -83.00% |
| 2013-06-30 | $-0.09B | $0.10B | -77.30% |
| 2013-03-31 | $-0.09B | $0.11B | -71.40% |
| 2012-12-31 | $-0.10B | $0.11B | -68.59% |
| 2012-09-30 | $-0.10B | $0.13B | -60.38% |
| 2012-06-30 | $-0.10B | $0.15B | -56.82% |
| 2012-03-31 | $-0.10B | $0.17B | -50.81% |
| 2011-12-31 | $-0.11B | $0.19B | -49.32% |
| 2011-09-30 | $-0.12B | $0.21B | -50.15% |
| 2011-06-30 | $-0.13B | $0.23B | -62.04% |
| 2011-03-31 | $-0.15B | $0.25B | -91.92% |
| 2010-12-31 | $-0.14B | $0.28B | -146.60% |
| 2010-06-30 | $-0.09B | 0.00% | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Instruments Manufacturing | $0.318B | $0.154B |
| Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA. PacBio's products are based on Single Molecule, Real-Time (SMRT) technology. SMRT generates long reads that help in assembling a whole human genome from scratch, without using an existing reference genome as a template. This process is known as de novo assembly. To observe DNA replication process smoothly, PacBio offers the SMRT Cell, Phospholinked nucleotides and The PacBio RS II System. The PacBio RS II System includes the PacBio RS II instrument, consumables and software. PacBio launched its new Sequel system based on SMRT technology. PacBio deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency was resolved. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Intuitive Surgical (ISRG) | United States | $200.815B | 87.96 |
| Thermo Fisher Scientific (TMO) | United States | $152.859B | 18.49 |
| Edwards Lifesciences (EW) | United States | $45.098B | 29.57 |
| Alcon (ALC) | Switzerland | $43.243B | 29.22 |
| IDEXX Laboratories (IDXX) | United States | $41.175B | 47.32 |
| DexCom (DXCM) | United States | $33.592B | 51.92 |
| IQVIA Holdings (IQV) | United States | $24.294B | 13.61 |
| STERIS (STE) | Ireland | $24.256B | 26.75 |
| Mettler-Toledo (MTD) | United States | $23.762B | 28.26 |
| Waters (WAT) | United States | $20.923B | 29.52 |
| SONOVA HOLDING (SONVY) | Switzerland | $19.641B | 0.00 |
| Hologic (HOLX) | United States | $12.421B | 13.50 |
| Sysmex ADR (SSMXY) | Japan | $10.695B | 30.34 |
| Penumbra (PEN) | United States | $10.662B | 83.68 |
| Masimo (MASI) | United States | $8.371B | 30.88 |
| Globus Medical (GMED) | United States | $7.953B | 18.65 |
| Teleflex (TFX) | United States | $5.589B | 9.23 |
| Glaukos (GKOS) | United States | $5.235B | 0.00 |
| Integer Holdings (ITGR) | United States | $4.155B | 21.77 |
| TransMedics (TMDX) | United States | $4.120B | 89.57 |
| PROCEPT BioRobotics (PRCT) | United States | $3.215B | 0.00 |
| LivaNova (LIVN) | United Kingdom | $2.389B | 14.23 |
| Veracyte (VCYT) | United States | $2.231B | 31.31 |
| Nihon Kohden (NHNKY) | Japan | $2.102B | 24.11 |
| Elekta AB (EKTAY) | Sweden | $2.048B | 18.41 |
| Alphatec Holdings (ATEC) | United States | $1.862B | 0.00 |
| Tandem Diabetes Care (TNDM) | United States | $1.512B | 0.00 |
| Artivion (AORT) | United States | $1.237B | 115.88 |
| Pulse Biosciences (PLSE) | United States | $1.109B | 0.00 |
| OPKO Health (OPK) | United States | $1.055B | 0.00 |
| Integra LifeSciences Holdings (IART) | United States | $1.011B | 5.38 |
| SiBone (SIBN) | United States | $0.805B | 0.00 |
| IRadimed (IRMD) | United States | $0.685B | 34.75 |
| Mesa Laboratories (MLAB) | United States | $0.659B | 14.41 |
| Beta Bionics (BBNX) | United States | $0.597B | 0.00 |
| AVANOS MEDICAL, INC (AVNS) | United States | $0.590B | 9.17 |
| NeuroPace (NPCE) | United States | $0.560B | 0.00 |
| Delcath Systems (DCTH) | United States | $0.559B | 0.00 |
| OrthoPediatrics (KIDS) | United States | $0.555B | 0.00 |
| RxSight (RXST) | United States | $0.541B | 0.00 |
| AxoGen (AXGN) | United States | $0.537B | 0.00 |
| ORTHOFIX MEDICAL INC (OFIX) | United States | $0.476B | 0.00 |
| Treace Medical Concepts (TMCI) | United States | $0.425B | 0.00 |
| AngioDynamics (ANGO) | United States | $0.372B | 0.00 |
| ClearPoint Neuro (CLPT) | United States | $0.362B | 0.00 |
| Semler Scientific (SMLR) | United States | $0.355B | 9.43 |
| Neuronetics (STIM) | United States | $0.283B | 0.00 |
| Tactile Systems Technology (TCMD) | United States | $0.224B | 13.59 |
| Alpha Tau Medical (DRTS) | Israel | $0.208B | 0.00 |
| Sight Sciences (SGHT) | United States | $0.177B | 0.00 |
| Spectral Diagnostics (EDTXF) | Canada | $0.171B | 0.00 |
| LENSAR (LNSR) | United States | $0.166B | 0.00 |
| Accuray (ARAY) | United States | $0.164B | 0.00 |
| 908 Devices (MASS) | United States | $0.162B | 0.00 |
| CVRx (CVRX) | United States | $0.161B | 0.00 |
| Inogen (INGN) | United States | $0.155B | 0.00 |
| Anteris Technologies Global (AVR) | Australia | $0.143B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.141B | 0.00 |
| Rapid Micro Biosystems (RPID) | United States | $0.134B | 0.00 |
| Lucid Diagnostics (LUCD) | United States | $0.133B | 0.00 |
| Atossa Genetics (ATOS) | United States | $0.127B | 0.00 |
| Microbot Medical (MBOT) | United States | $0.097B | 0.00 |
| Monogram Orthopaedics (MGRM) | United States | $0.097B | 0.00 |
| Sensus Healthcare (SRTS) | United States | $0.077B | 46.60 |
| InspireMD (NSPR) | Israel | $0.073B | 0.00 |
| EnVVeno Medical (NVNO) | United States | $0.067B | 0.00 |
| EDAP TMS S.A (EDAP) | France | $0.066B | 0.00 |
| Biosig Technologies (BSGM) | United States | $0.062B | 0.00 |
| Zomedica (ZOMDF) | United States | $0.058B | 0.00 |
| Hyperfine (HYPR) | United States | $0.047B | 0.00 |
| Vicarious Surgical (RBOT) | United States | $0.043B | 0.00 |
| Precision Optics (POCI) | United States | $0.037B | 0.00 |
| Envoy Medical (COCH) | United States | $0.035B | 0.00 |
| Spectral AI (MDAI) | United States | $0.034B | 0.00 |
| Baird Medical Investment Holdings (BDMD) | $0.034B | 0.00 | |
| DarioHealth (DRIO) | United States | $0.029B | 0.00 |
| Adagio Medical Holdings (ADGM) | United States | $0.019B | 0.00 |
| NexGel (NXGL) | United States | $0.018B | 0.00 |
| Ekso Bionics Holdings (EKSO) | United States | $0.012B | 0.00 |
| PAVmed (PAVM) | United States | $0.011B | 0.00 |
| SINTX TECHNOLOGIES, INC (SINT) | United States | $0.008B | 0.00 |
| Tenon Medical (TNON) | United States | $0.008B | 0.00 |
| WORK Medical Technology Group (WOK) | China | $0.008B | 0.00 |
| Inspira Technologies OXY B.H.N (IINN) | Israel | $0.007B | 0.00 |
| Check-Cap (CHEK) | Israel | $0.005B | 0.00 |
| Autonomix Medical (AMIX) | United States | $0.005B | 0.00 |
| ReShape Lifesciences (RSLS) | United States | $0.004B | 0.00 |
| Nuwellis (NUWE) | United States | $0.004B | 0.00 |
| Venus Concept (VERO) | Canada | $0.003B | 0.00 |
| ENDRA Life Sciences (NDRA) | United States | $0.002B | 0.00 |
| Helius Medical Technologies (HSDT) | United States | $0.002B | 0.00 |
| Avinger (AVGR) | United States | $0.002B | 0.00 |
| Nanovibronix (NAOV) | United States | $0.001B | 0.00 |
| Bluejay Diagnostics (BJDX) | United States | $0.001B | 0.00 |
| Accelerate Diagnostics (AXDX) | United States | $0.001B | 0.00 |
| Spinal Elements Holdings (SPEL) | United States | $0.000B | 0.00 |
| Fresenius Medical Care AG KGaA (FMS) | Germany | $0.000B | 16.23 |
| Longview Acquisition II (LGV) | United States | $0.000B | 0.00 |